#AACR21 Transcriptional analyses identified 4 subtypes of #SCLC w/ distinct immunological characteristics. Patients w/ the SCLC-I subtype experienced greater benefit with the addition of #atezolizumab to #cisplatina etoposide as first-line (1L) treatment: bit.ly/3dYwrMl

This is the most comprehensive TMB analysis to date. The results do not support its application as a universal biomarker for response to immunotherapy. More information: bit.ly/2REi7jy #cancer #tumorburden #biomarkers #TMB #immunotherapy #oncology #OncoAmericas

The researchers concluded that the higher dose of radiotherapy led to a survival gain compared to 45 Gy, without increase in toxicity. Read the full details: bit.ly/3vYL74p #cancer #lungcancer #SCLC #radiotherapy #oncology #OncoAmericas

Genetically engineered #herpes simplex virus type 1 G207 converted "cold" tumors into "hot" ones, observing a dramatic increase in tumor-infiltrating lymphocytes in the microenvironment of the #gliomas. Check out the results published on NEJM: bit.ly/3eLfZzP

The short-term safety of the BNT162b2 mRNA vaccine was similar in cancer patients receiving immunotherapy compared to healthy individuals. More information: bit.ly/3eNNv8m #cancer #COVID19 #vaccine #mRNA #immunotherapy #oncology #OncoAmericas

Meta-analysis presented in #ESMOBreast21 demonstrated that neoadjuvant therapy associated with #immunotherapy significantly increased the pCR rate in patients with triple-negative breast #cancer, regardless of PD-L1 status: bit.ly/342u3yI

Preliminary data from the study presented at ESMO Breast Cancer 2021 suggest that short-term use of neoadjuvant denosumab increases the number of tumor-infiltrating lymphocytes. More information: bit.ly/3u4m5zn #ESMOBreast21 #breastcancer

#RAD51 independently predicts clinical benefit from adding carboplatin to neoadjuvant chemotherapy in triple-negative #breastcancer TNBC. Analysis of the GeparSixto trial was presented during #ESMO Breast Cancer 2021: bit.ly/34eorBw

Clinical Oncologist at Grupo Oncoclínicas discusses phase II DESTINY-Breast01 study and meta-analysis that included four randomized clinical trials involving patients with triple-negative breast cancer: bit.ly/2TeQjTw #OncoAmericas #ESMO #ESMOBreastCancer #breastcancer

Trial, presented during #ASCO21, evaluated pembrolizumab versus placebo in patients with stage III cutaneous melanoma with complete lymph node resection. The antibody produced a promising and sustained response rate, but the efficacy was lower: bit.ly/3yc7KDM

The efficacy and safety of adjuvant gefitinib for patients with completely resected EFGR-mutated non-small cell lung cancer (NSCLC) versus cisplatin-based adjuvant chemotherapy are not fully known. Learn more: bit.ly/2UiatMY #ASCO21 #lungcancer #gefitinib #adjuvant

177Lu-PSMA-617 is a targeted radioligand therapy that distributes ß-particle radiation to cells expressing PSMA and to the surrounding microenvironment. Learn more about the study presented during ASCO 2021 bit.ly/3hzmhCO #ASCO21 #prostate #luterium #VISION #OncoAmericas

The study concluded that pembrolizumab provides statistically higher PFS gain compared to chemotherapy with fewer adverse events, showing a trend in mortality reduction that, however, did not reach statistical significance. Learn more: bit.ly/3dBCsyf #ASCO21 #colon

Patients with HER2+ metastatic breast cancer are at high risk of developing brain metastases and treatment options are limited when secondary involvement lesions arise in the central nervous system (CNS). More information: bit.ly/3dJywLS #ASCO21 #mama #trastuzumab

Differential expression of immune genes and predictive biomarkers in SCLC subtypes may indicate therapeutic targets for personalized treatment approaches. The analysis represents the largest real-world dataset evaluated by whole transcriptome sequencing: bit.ly/3yuQJ7T

Study, presented during #ASCO21, evaluated nivolumab as adjuvant therapy in patients with resected (R0) stage II or III esophageal or gastroesophageal junction cancer who had residual pathologic disease after treatment with neoadjuvant chemoradiotherapy: bit.ly/2SRdUKr

The addition of famitinib to camrelizumab and nab-paclitaxel showed promising antitumor activity as first-line treatment in patients with immunomodulatory TNBC, with a manageable toxicity profile. Learn more about the study presented during ASCO 2021: bit.ly/3qOsOxB

A real-world trial, presented during ASCO 2021, evaluated real-world biomarkers testing rates in patients with metastatic non-small cell lung cancer (mNSCLC) under first-line systemic therapy. More information: bit.ly/3dUwsAO

Both nivolumab combined with chemotherapy and ipilimumab demonstrated superior OS versus chemotherapy alone, as well as sustained objective responses and acceptable safety in advanced esophageal SCC. Read more about CheckMate 648 presented at ASCO 2021: bit.ly/3qSxJNM

A randomized, phase II trial investigating the neoadjuvant use of durvalumab combined with anthracycline and taxane-based chemotherapy in the treatment of early triple-negative breast cancer (TNBC) was presented during the ASCO World Congress 2021: bit.ly/3yPc5wN